EP1032699A1 - Acide gamma-polyglutamique (gamma-pga) a masse moleculaire elevee - Google Patents
Acide gamma-polyglutamique (gamma-pga) a masse moleculaire eleveeInfo
- Publication number
- EP1032699A1 EP1032699A1 EP98960252A EP98960252A EP1032699A1 EP 1032699 A1 EP1032699 A1 EP 1032699A1 EP 98960252 A EP98960252 A EP 98960252A EP 98960252 A EP98960252 A EP 98960252A EP 1032699 A1 EP1032699 A1 EP 1032699A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pga
- molecular weight
- solution
- cells
- cell culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920002643 polyglutamic acid Polymers 0.000 title description 122
- 238000004113 cell culture Methods 0.000 claims abstract description 39
- 239000002738 chelating agent Substances 0.000 claims abstract description 13
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 19
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 18
- 238000009295 crossflow filtration Methods 0.000 claims description 17
- 239000001509 sodium citrate Substances 0.000 claims description 14
- 229940038773 trisodium citrate Drugs 0.000 claims description 14
- 241000194108 Bacillus licheniformis Species 0.000 claims description 12
- 229960004106 citric acid Drugs 0.000 claims description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 5
- 150000001768 cations Chemical class 0.000 claims description 5
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 5
- 238000011026 diafiltration Methods 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 230000004888 barrier function Effects 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 238000005453 pelletization Methods 0.000 claims 1
- 108700022290 poly(gamma-glutamic acid) Proteins 0.000 description 118
- 239000000243 solution Substances 0.000 description 33
- 239000013587 production medium Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 12
- 229960001484 edetic acid Drugs 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- 238000012545 processing Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 238000000569 multi-angle light scattering Methods 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229960002989 glutamic acid Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000011218 seed culture Methods 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000010979 pH adjustment Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- LXOPBRWTWGELKY-HVDRVSQOSA-N (2s)-2-aminopentanedioic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O LXOPBRWTWGELKY-HVDRVSQOSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Definitions
- ⁇ -PGA ⁇ -Poly (glutamic acid), hereinafter " ⁇ -PGA”
- ⁇ -PGA can be synthesized as a capsule by certain microorganisms, such as Bacillus licheniformis (Bacillus subtilis) using specific media formulations.
- the utility and yield of the polymer have been limited by, among other factors, the limited and heterogenous size of the polymer compounded by uncontrolled degradation of ⁇ -PGA that typically occurs consequent to isolation and purification steps.
- ⁇ -PGA having a molecular weight no greater than 2.5xl0 6 g/mol generally is separated from cell cultures by processing the cells in a high-shear apparatus, such as a blender.
- the invention is directed to a method of synthesizing ⁇ -PGA of a high molecular weight, for separating ⁇ -PGA from cells of a cell culture and to a method for fractionating ⁇ -PGA from a ⁇ -PGA-containing cell culture.
- the invention also is directed to ⁇ -PGA of high molecular weight and a purified ⁇ -PGA composition.
- high molecular weight ⁇ -PGA is produced using a broth comprising trisodium citrate.
- high molecular weight ⁇ -PGA is produced using a starting inoculum of cells cryopreserved from a culture grown in a medium that includes trisodium citrate.
- the method of producing high molecular weight ⁇ -PGA comprises culturing Bacillus licheniformis cells in a broth comprising trisodium citrate, cryopreserving the cultured cells as a 1:1 colution with 20% glycerol and culturing the cryopreserved cells, whereby the cells produce high molecular weight ⁇ -PGA.
- the present invention is further directed toward cryopreserved Bacillus licheniformis bacteria, wherein the bacteria have been cultured in broth comprising trisodium citrate and wherein the cultured bacteria have been preserved in a 1:1 solution with 20% glycerol.
- high molecular weight ⁇ -PGA is produced using a broth comprising citric acid monohydrate, wherein the citric acid monohydrate has been dissolved in water and the pH of the citric acid solution adjusted to about pH 6.0 prior to its addition to the broth.
- the present invention is also drawn to a method of separating ⁇ -PGA from the cells of a ⁇ -PGA-producing cell culture.
- the method of separating ⁇ -PGA from cells of a cell culture includes lowering the pH of the cell culture to about pH 2. The ⁇ -PGA is then separated from the cells.
- Another embodiment of the invention includes fractioning the ⁇ -PGA directly from a cell culture by lowering the pH of the cell culture to about pH 2 and subjecting the cell culture to tangential flow filtration.
- the invention relates to a method for increasing viscosity of a ⁇ -PGA solution. The method includes treating the ⁇ -PGA solution with a chelator to remove metal ions bound to the ⁇ -PGA and then removing the chelator, resulting in ⁇ -PGA having higher viscosity and lower metal ion content.
- the present invention is directed to purified ⁇ -PGA having a molecular weight of at least about 2.5 x 10 6 g/mol.
- the present invention provides purified ⁇ -PGA composition having a relatively high molecular weight.
- High molecular weight ⁇ -PGA is produced using the production media described herein or the cryopreserved cells as described herein.
- Lowering of the pH of the ⁇ -PGA- containing cell culture allows separation of the high molecular weight ⁇ -PGA from the cells under relatively low- shear conditions, such as centrifugation at low g-force, or filtration using a low shear filtration device resulting in higher average molecular weight of the isolated ⁇ -PGA, less contamination with bacterial cell components and better yield.
- ⁇ -PGA of relatively high viscosity and low metal ion content, thereby potentially providing greater utility for the purified ⁇ -PGA.
- ⁇ -PGA produced by the method of the invention and having a reduced metal ion content can have a significantly increased capacity to bind metal ions and can be used as a chelator of metal ions.
- ⁇ -Poly (glutamic acid) includes repeating units of glutamic acid that are linked between ⁇ -amino and ⁇ - carboxylic acid functional groups of the glutamic acid.
- ⁇ -PGA has the following structural formula:
- n generally is in the range of between about one thousand and over twenty thousand.
- a salt of the ⁇ -PGA has the following structural formula:
- n generally is in the range of between about one thousand and over twenty thousand and "M” can be, for example, a suitable metal, such as sodium.
- the invention is directed to a method of producing ⁇ -PGA having high molecular weight (for example, a molecular weight greater than 2.5 x 10 6 g/mol) .
- the invention is directed to preventing significant degradation of ⁇ -PGA molecular weight during isolation and purification.
- Various embodiments of the method include separation of ⁇ -PGA from a culture broth, and treatment of the ⁇ -PGA after isolation.
- ⁇ -PGA can be separated from cells, such as Bacillus subtilis or Bacillus licheniformis , cultured in a suitable production broth.
- a suitable production broth can be formed from a seed broth, such as that described by Kunioka and Gotoh (Applied Microbiology and Biotechnology, 40:1031- 1035 (1993)), and by R.L. Stock, II (Masters Thesis, "Rheological Characterization of (Poly- ⁇ ) Glutamic Acid Fermentations," August 1996, Worcester Polytechnic Institute) .
- the seed broth is inoculated with B . licheniformis, strain ATCC 9945A, obtained from American Type Tissue Collection. A 2% to 6% dilution of inoculum in seed broth typically is employed.
- higher viscosities are achieved as a result of employing a higher (6%) concentration of inoculum in the seed broth, indicating higher molecular weight and/or higher yield of polymer.
- the inoculated seed broth is cultured for a suitable period of time under suitable conditions, until the cells reach a late exponential/early stationary phase.
- the seed broth then is employed to inoculate a suitable production broth, such as that described in Example II.
- a 2% to 6% dilution seed culture to production broth typically is employed.
- a higher proportion of seed culture to production broth is employed to decrease the lag phase to production.
- the seeded production broth referred to herein as the cell culture
- the seeded production broth is cultured for a suitable period of time under suitable conditions to allow maximum production of ⁇ - PGA.
- the culture is incubated for sixty-six hours at 37°C at 250 RPM in a rotary shaker.
- the cell culture can be fermented in a fermenter, allowing shorter incubation times.
- the culture is incubated for forty-eight hours at 37 °C.
- Fermentation time can be reduced by, for example, feeding pure oxygen to the cell culture at no more than about 5 % saturation of the solution with dissolved oxygen.
- Cell culture viscosity is monitored during incubation and increases during production of ⁇ -PGA. Generally, the viscosity will begin to decrease late in the production phase.
- the ⁇ -PGA is harvested from the cell culture prior to this decrease to preserve molecular weight and yield.
- high molecular weight ⁇ -PGA is produced using standard production medium (described in Example I) comprising trisodium citrate at a suitable concentration.
- the trisodium citrate is present at a concentration of about 50 to about 100 g/L.
- the trisodium citrate is present at a concentration of about 60 to about 65 g/L.
- the trisodium citrate is present at a concentration of 61.4 g/L.
- the high molecular weight ⁇ -PGA is produced using standard production medium wherein the citric acid monohydrate is dissolved in water and the pH of the citric acid solution adjusted to 6.0 with NaOH, prior to its addition to the production medium.
- high molecular weight ⁇ -PGA is produced using standard production medium wherein the medium is pH adjusted with semi-conductor grade (99.99% pure) NaOH. While not being bound by theory, it is believed that the trisodium salt of citric acid is not as strongly an acidic compound because hydrogen has been replaced by sodium. When using trisodium citrate in culture medium, less sodium hydroxide is used for the final pH adjustments of the medium to 7.0 (normally, because citric acid glutamic acids are present in the medium, large amounts of sodium hydroxide are used for pH adjustment) . Reagent grade sodium hydroxide contains trace metal (and possibly other) contaminants. Therefore, effectively less trace metals or other contaminants may be present in the trisodium medium compared to the standard production medium.
- a standard production medium formulation protocol calls for addition of all the dry ingredients plus glycerol, followed by pH adjustment to 7.0 with sodium hydroxide.
- the citric acid added in this form has already been neutralized. Since citric acid has three pKa's or three effective buffering regions, the final form of citric acid present in the medium may be altered when using the trisodium salt of citric acid compared to the monohydrate.
- cells having been grown in standard production medium comprising trisodium citrate are cryopreserved in about a 1:1 ratio with about 20% glycerol.
- Cells thus cryopreserved can be grown in standard production medium to obtain high molecular weight ⁇ -PGA.
- High molecular weight ⁇ -PGA is separated from cells of the cell culture by the method of the present invention.
- the temperature of the cell culture is reduced to at least room temperature and, thereafter, the pH of the cell culture is adjusted or reduced, by adding a suitable acid, such as concentrated HCl, to about pH 2 or below.
- the cell culture is then centrifuged under relatively low-shear conditions, such as 10,000 x g or less, to pelletize the bacteria.
- the cell culture can be diluted with a suitable solvent, such as water, or a solution of citric acid having a concentration of about 0.1 M to about 1 M and at about pH 2, thereby lowering the viscosity and allowing centrifugation at a lower g-force, such as about 6,000 x g.
- a suitable solvent such as water
- a solution of citric acid having a concentration of about 0.1 M to about 1 M and at about pH 2, thereby lowering the viscosity and allowing centrifugation at a lower g-force, such as about 6,000 x g.
- a suitable solvent such as water
- a solution of citric acid having a concentration of about 0.1 M to about 1 M and at about pH 2
- a solution of citric acid having a concentration of about 0.1 M to about 1 M and at about pH 2
- the supernatant is separated from the pelletized material resulting in ⁇ -PGA supernatant.
- the ⁇ -PGA supernatant can be analyzed for
- the ⁇ -PGA can be separated from the cells of the cell culture by tangential flow filtration (TFF) .
- TFF tangential flow filtration
- a TFF device equipped to handle high viscosity fluids is used (such as a Millipore Prostak ® system) to filter the fermentation broth (relative shear rates are at least 10 times higher in the Millipore Pellicon ® system) .
- the culture is harvested as described above. This step as opposed to the centrifugation step alone removes all cellular debris, which is critical for pharmaceutical applications.
- the pH of the resulting ⁇ -PGA supernatant or ⁇ -PGA filtrate can be raised to at least about pH 6 to reduce or minimize hydrolysis of ⁇ -PGA in subsequent processing steps.
- a suitable base such as NaOH
- the method of the present invention involves fractionating ⁇ -PGA directly from a cell culture comprising subjecting the cell culture to TFF.
- the pH of the cell culture is adjusted or lowered with a suitable acid, such as HCl, to about pH 3 or below.
- the pH-adjusted cell culture is subjected to TFF to remove the bacteria using a Millipore filtration system equipped for high viscosity fluids such as Prostak ® .
- a fraction of ⁇ -PGA having a lower molecular weight can be separated from the cell culture by processing the pH adjusted broth through TFF filtration units in a high shear configuration, such as Minitan ® or Pellicon ® (Millipore) . Centrifugation or TFF filtration can be combined with size fractionation using conventional techniques such as filtration employing filter units having the desired molecular weight cut-off, or by size exclusion chromatography. For example, a filter unit having a 100,000 molecular weight cut-off is employed to separate ⁇ -PGA into lower and higher molecular weight fractions. In this manner, ⁇ -PGA of defined molecular weight and low poly dispersity is isolated from the high molecular weight polymer.
- ⁇ -PGA can be concentrated in solution by employing TFF, whereby the molecular weight barrier of the tangential filtration device is smaller than the ⁇ -PGA molecular weight of interest .
- ⁇ -PGA can be fractionated using a microfluidizer (Microfluidics, Massachusetts) cell disrupter.
- the device is normally used to generate high sheer to disrupt bacterial cells.
- the device is designed for continuous operation such that material from a reservoir is pumped into the device and processed effectively a fluid element at a time, the ⁇ -PGA solution is run through the unit for one pass only. Therefore, while each fluid element is being sheered or fractionated, the remainder of the solution is stable in the reservoir or in the collection vessel.
- the device can be operated at a range of PSI. In one embodiment, the device is operated at a PSI of about 1,000 to about 20,000.
- the method of the present invention includes increasing viscosity of a ⁇ -PGA solution.
- a suitable chelator such as ethylenediamine tetra-acetic acid (EDTA) or EGTA is added to the ⁇ -PGA supernatant, or ⁇ -PGA filtrate, to remove metal ions bound to the ⁇ -PGA.
- the ⁇ -PGA solution is dialyzed against an EDTA-containing solution at a concentration sufficient to remove divalent cations bound to the ⁇ -PGA.
- the EDTA is at a concentration of between about 1 and about 10 M.
- the concentration of EDTA is about 2 mM or higher.
- the ⁇ -PGA solution is processed by diafiltration employing TFF and an EDTA-containing solution.
- the diafiltration includes constant volume washing of ⁇ -PGA supernatant or ⁇ -PGA filtrate with an EDTA-containing solution.
- the chelator is then removed from the solution by a suitable method, such as dialysis or diafiltration, against a suitable medium, such as water or an appropriate buffer and the ⁇ -PGA solution is lyophilized.
- a suitable medium such as water or an appropriate buffer
- an ammonium carbonate buffer can be used since, upon lyophilization, ammonia and C0 2 is liberated, leaving pure ⁇ -PGA as a fine white powder.
- a buffer solution of high ionic strength is employed, dramatically reducing the fluid viscosity during this stage of processing, thereby decreasing processing time.
- the buffer solution is at a concentration of least about 200 mM to about 400 mM.
- processing of the ⁇ -PGA supernatant or ⁇ -PGA filtrate is facilitated by diluting the ⁇ -PGA solution to further reduce the viscosity.
- removal of metal ions from ⁇ - PGA causes the ⁇ -PGA to have an increased capacity for heavy metal uptake.
- the ⁇ -PGA having increased capacity for heavy metal uptake can be employed in environmental applications, such as water treatment to remove heavy metals .
- the ⁇ -PGA of the invention includes ⁇ -PGA molecules of molecular weight greater than about 2.5 x 10 6 g/mol.
- the ⁇ -PGA of the present invention has a molecular weight of about 4 to 8 x 10 6 g/mol. In other embodiments, the molecular weight can be at least about 8 x 10 6 or 10 x 10 6 .
- ⁇ -PGA having a molecular weight of at least 1 x 10 8 has been purified using the method of the present invention.
- the purified ⁇ -PGA preparation has less than about 8 ⁇ g of uronic acid per milligram of ⁇ -PGA.
- the fractionated ⁇ -PGA of the present invention has a polydispersity of about 1.4 to 1.6.
- Bacillus licheniformis ATTC#9945 The cells were grown in a seed broth consisting of 10 g/L peptone, 2 g/L yeast extract, and 0.02 g/L MgS0 4 -7H 2 0 (Kunioka and Gotoh, Applied Microbiology and Biotechnology, 40:1031-1035). The cells were grown overnight ( ⁇ 8 hr.) At 250 rpm and 37°C. A volume of 0.9 mL of the cells was then aseptically transferred to forty 1 mL cyrovials to which 0.1 mL of glycerol was added. The vials were then shaken vigorously and stored at -20°C. These vials were used to initiate all experiments.
- the frozen cells were rapidly thawed in a temperature bath at 37°C and 50 mL of seed broth was inoculated with the thawed cells.
- the inoculated seed broth (seed culture) was then grown at 250 rpm on a rotary shaker and 37°C.
- the seed culture was then added aseptically to standard production medium at a volumetric ratio of 2%.
- the production medium was a modified form of Medium E (Thorne et al .
- Fermentation times ranged from 3 to 5 days.
- the molecular weight range obtained medium was 2-3 x 10 6 Da, which corresponded to a viscosity (at zero shear) , for a 2 or 4% (w/v) solution at 25°C of 20,000 and 65,000 cP, respectively.
- the yield of purified PGA was approximately 15 g/1.
- viscosity of the fermentation broth was extremely high, and exhibited significant normal forces (similar to bread dough which causes the dough to "climb" up a mixer shaft) .
- the viscosities obtained for 2 and 4% solutions at 25°C were 28,000 and as high as 150,000 cP. Since equivalent concentrations of material were involved, the only factor which could affect the viscosity under these conditions was molecular weight. Branching of the molecule could also affect viscosities, but no significant branching effect of the molecule was found.
- the molecular weight of the ⁇ -PGA was 4 - 6 x 10 6 Da. The yield was 12 g/1. Control fermentations using medium developed by Thorne, et al , J. Bacteriology, 68:307-315 (1957) had a viscosity under the same conditions for analysis (2% solution at 25°C) of only 200 cP, however, the yield was as high as 40 g/1.
- the fermentation of ⁇ -PGA producing bacteria cultured in the above described medium was performed in shake flasks and in bioreactors .
- the conditions in the 4 liter bioreactors were the following: agitation speed - 200 RPM, temperature - 37°C and aeration - 5L/min.
- Impellers used in the fermenter were three 6-bladed Rushton turbines. Similar molecular weight and viscosity was obtained in the fermenter.
- Alternate Media Formula tions Alternate media formulations that yielded high molecular weight ⁇ -PGA are 1) production medium described under Example I that was pH adjusted with semi-conductor grade sodium hydroxide (99.99% pure), and 2) medium described under Example I, wherein prior to its addition, the citric acid monohydrate was dissolved in water and the pH of the citric acid solution adjusted to pH 6.0 with reagent grade sodium hydroxide. Al terna te Cryopreservation
- Example II Cells were grown in production medium of Example II until an optimal density was obtained (typically exponential phase) .
- An equal volume of cell culture and 20% glycerol were mixed and immediately stored at -80 °C in appropriate aliquots.
- 1 ml of cryopreserved cells was thawed at room temperature and added to 50 ml of seed broth (described in Example I) . After 8 hours of incubation as described, the optical density of the culture at 600nm was approximately 1. Two ml at these exponential phase cells were inoculated into 50ml of production broth and incubated as described.
- pH Adj ustmen t The culture was harvested by reducing the temperature of the fermentation broth to at least room temperature or cooler. The temperature was reduced because addition of acid has a tendency to increase the temperature, which increases the degradation rate of the polymer during processing. After cooling, the pH of the broth was reduced (using concentrated HCl) to approximately 2.0. Typically, 300 ml of concentrated HCl was used per 5 liters of culture. The material was then centrifuged at approximately 10,000 - 15,000 x g for 20 minutes. During centrifugation, a pellet forms which can be easily decanted. ⁇ -PGA produced via the low shear method described herein has ten-fold less contaminants (see Table 1) than was cited by McLean, et al . ⁇ Applied and Environmental Microbiology, 56:3617-3677).
- the clarified broth (broth after cell removal) was dialyzed using 12,000 molecular weight cut-off dialysis tubing.
- the first dialysis was performed against a 10 mM solution of EDTA.
- the concentration of EDTA can be in the range of 1 mM to 100 mM.
- MALLS Sta tic Mul tiple Angle Laser Light Scattering
- the molecular weight of ⁇ -PGA prepared as described above (through Example III) was measured using SEC, a standard method in the art.
- a TSK G ⁇ OOOPWxL column (ToSoHaaS, Montgomeryville, PA) was equilibrated with 0.4 M phosphate buffer (pH 4.5).
- Polyethylene oxide of molecular weight 1 x 10 6 g/mol and 8 x 10 6 g/mol (PEOl and PE08, respectively) were used for comparison.
- the molecular weight of ⁇ -PGA was well above 1 x 10 6 g/mol and very likely near 8 x 10 6 g/mol, in agreement with the static MALLS analysis.
- Example VI Fractionating PGA during Purification
- Fractionated ⁇ -PGA having lower molecular weight with low polydispersity was produced by filtering the pH- adjusted broth of Example 2 using a Minitan ® (Millipore) filtration device. The broth was circulated through the filter system such that only cleaved polymer passed through the filter, resulting in fractionated ⁇ -PGA of low polydispersity.
- Minitan ® Micropore
- ⁇ -PGA was prepared according to the method of the present invention and separated from the cells.
- a ⁇ -PGA solution (up to 2% w/v) was prepared in deionized water and allowed to dissolve completely (overnight at 4°C) .
- the ⁇ -PGA solution was processed through a Microfluidizer (Microfluidics, Massachusetts) cell disrupter. The device was used as described in the manufacturer' s instructions except using a cell-free solution. A pressure range of 1,000 up to 20,000 PSI was used.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polyamides (AREA)
Abstract
L'invention concerne un η-PGA à masse moléculaire élevée. On sépare le η-PGA des cellules d'une culture de cellules productrice de η-PGA après avoir réglé le pH de la culture cellulaire à un niveau inférieur à 3 environ. De plus on augmente la viscosité de la solution η-PGA par le retrait d'ions métallique à l'aide d'un chélateur. Le η-PGA est en outre séparé par fractionnement directement dans une culture cellulaire de manière que ce η-PGA fractionné présente une faible polydispersité. On obtient ainsi un η-PGA purifié présentant une masse moléculaire d'au moins 2,5 x 106.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6694297P | 1997-11-18 | 1997-11-18 | |
| US66942P | 1997-11-18 | ||
| PCT/US1998/024580 WO1999025864A2 (fr) | 1997-11-18 | 1998-11-18 | ACIDE η-POLYGLUTAMIQUE (η-PGA) A MASSE MOLECULAIRE ELEVEE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1032699A1 true EP1032699A1 (fr) | 2000-09-06 |
Family
ID=22072718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP98960252A Withdrawn EP1032699A1 (fr) | 1997-11-18 | 1998-11-18 | Acide gamma-polyglutamique (gamma-pga) a masse moleculaire elevee |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1032699A1 (fr) |
| CA (1) | CA2310631A1 (fr) |
| WO (1) | WO1999025864A2 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004028548A2 (fr) * | 2002-09-26 | 2004-04-08 | Carbomer, Inc. | Agents neuroprotecteurs |
| DE102004030938A1 (de) | 2004-06-26 | 2006-01-12 | Henkel Kgaa | Neue, Polyaminosäuren bildende oder abbauende Genprodukte von Bacillus licheniformis und darauf aufbauende verbesserte biotechnologische Produktionsverfahren |
| WO2011127221A1 (fr) | 2010-04-09 | 2011-10-13 | National Health Research Institutes | Solutions d'irrigation oculaire à base d'acide gamma-polyglutamique |
| CN103665371B (zh) * | 2013-11-14 | 2016-03-02 | 天津北洋百川生物技术有限公司 | 一种利用超滤纳滤技术精制生物发酵液中聚谷氨酸的方法 |
| CN109609408B (zh) * | 2018-12-27 | 2022-04-15 | 黄河三角洲京博化工研究院有限公司 | 一株γ-聚谷氨酸高产菌株及利用该菌株进行液体发酵制备γ-聚谷氨酸的方法 |
| CN112480394A (zh) * | 2020-12-01 | 2021-03-12 | 广西大学 | 一种从高黏发酵液中分离纯化超高分子量聚γ-谷氨酸的方法 |
-
1998
- 1998-11-18 EP EP98960252A patent/EP1032699A1/fr not_active Withdrawn
- 1998-11-18 CA CA002310631A patent/CA2310631A1/fr not_active Abandoned
- 1998-11-18 WO PCT/US1998/024580 patent/WO1999025864A2/fr not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9925864A3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999025864A2 (fr) | 1999-05-27 |
| CA2310631A1 (fr) | 1999-05-27 |
| WO1999025864A3 (fr) | 1999-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5049264B2 (ja) | pH操作によるストレプトコッカス・ニューモニエ多糖からの混入物の分離 | |
| JP6825950B2 (ja) | 莢膜Streptococcus pneumoniae多糖の生産のための短縮された精製プロセス | |
| EP0137786B1 (fr) | Acide hyaluronique prepare a partir d'une de culture bacterienne | |
| EP2435578B1 (fr) | Production biotechnologique de chondroïtine | |
| AU6280194A (en) | Degradation of nucleic acids by peroxides | |
| EP1032699A1 (fr) | Acide gamma-polyglutamique (gamma-pga) a masse moleculaire elevee | |
| CA2063490A1 (fr) | Preparation extracellulaire d'homopolysaccharides de poids moleculaire eleve, son utilisation et ses souches fongiques | |
| WO2024131919A1 (fr) | Paenibacillus et son application à la préparation d'oligosaccharides de tremella fuciformis | |
| WO2022063770A1 (fr) | Procédé de récupération d'une protéine à partir d'un bouillon de fermentation comprenant un degré élevé de cellules lysées | |
| EP2952586B1 (fr) | Amélioration du rendement de polysaccharide capsulaire bactérien par addition d'agents antimousse | |
| JP2002176996A (ja) | 細菌細胞の表面に付着していないエキソポリサッカライドの産生 | |
| FI87934C (fi) | Framstaellningsfoerfarande foer ny vaermebestaendig transglukosidas | |
| EP0979301B1 (fr) | Souche de pseudomonas alginovora productrice d'alginate-lyase et son utilisation pour la depolymerisation d'alginate | |
| Ren et al. | Bioconversion of sugar beet molasses into functional exopolysaccharides by beet juice-derived lactic acid bacteria | |
| WO2001016302A1 (fr) | Nouvelle enzyme thermostable digerant le collagene, nouveau micro-organisme produisant l'enzyme et methode de production de l'enzyme | |
| US4904586A (en) | Enzymatic process for treating xanthan gums in order to improve the filterability of their aqueous solutions | |
| WO2022049228A1 (fr) | Procédé pour éliminer des agents antimousse à partir d'un bouillon de fermentation | |
| WO2008043892A1 (fr) | Nouveau polysaccharide, son procédé de préparation et ses utilisations notamment dans le domaine cosmétique | |
| JP4395380B2 (ja) | サイクロデキストラン高生産微生物とこれを用いたサイクロデキストランの製造法 | |
| Manzoni et al. | Influence of the culture conditions on extracellular lyase activity related to K5 polysaccharide | |
| CN116694703A (zh) | 一种无氮产胶发酵生产可得然胶的方法 | |
| KR20060084602A (ko) | 유기용매를 이용한 히알루론산 및 그 염의 입자 크기의조절방법 | |
| JPS58180426A (ja) | 抗腫瘍性物質 | |
| JPH01120281A (ja) | アセトバクター属細菌のスフェロプラスト調整方法 | |
| SI9800038A (sl) | Postopek za pridobivanje ekstracelularne keratinolitično aktivne proteaze |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20000619 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| D17D | Deferred search report published (deleted) | ||
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 12P 21/02 A, 7C 12N 1/20 B, 7C 12N 1/04 B, 7C 12N 1/20 J, 7C 12R 1:10 J, 7C 12P 21/02 K, 7C 12R 1:10 K |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20030531 |